Category: BÜHLMANN Calprotectin Assay Citations

A number of the publications in the citation list describe applications that are outside of product claims thus they should be used for information only.

Ulcerative Colitis Study: Correlation of Faecal Calprotectin with Histological Nancy Index

BÜHLMANN IBDoc®: Walsh, A, Kormilitzin, A. et al. New faecal calprotectin cut-off points for remission and active disease defined by UCEIS and Nancy indices in ulcerative colitis (UC).  13th Congress of ECCO 2018, Feb 14 – 17, 2018. Vienna, Austria. Highlights from this Poster “Conclusions. An FCal <180 g/g is indicative of endoscopic and histological remission. FCal
Continue Reading

Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®

BÜHLMANN IBDoc®: Wong, A, Bourdages, R. et al. Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®.  CDDW 2018, Feb 09 – 11, 2018. Toronto, ON Canada. Highlights from this Publication “Conclusions. The IBDoc® test kit was understood by participants, with a majority of participants finding it easy to use, with an
Continue Reading

Fecal Calprotectin Measurement is a Marker of Short-Term Clinical Outcome and Presence of Mucosal Healing in Patients with Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA: A.Kostas, S.I. Siakavellas, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World Journal of Gastroenterology; November 2017. PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387. Highlights from this Publication “In our patient cohort, we were able to define an optimal cut-off FC value of 261 µg/g, which had a
Continue Reading

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

BÜHLMANN fCAL® ELISA Citation:  Beswick, L. et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study.  Journal of Crohn's and Colitis. 2017 Nov 7. DOI: 10.1093/ecco-jcc/jjx146.  PMID:  29121178 . Highlight from this Publication “In ASUC, post-first dose IFX, early assessment of serum/faecal IFX, calprotectin and partial Mayo scores can accurate predict future
Continue Reading

Analytical and Diagnostic Performance of Two Automated Fecal Calprotectin Immunoassays for Detection of Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA: De Sloovere, M. et al. Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease, Clin Chem Lab Med. 2017 Aug 28;55(9):1435-1446. PMID: 28076305  DOI: 10.1515/cclm-2016-0796. Highlights from this Publication ““Bühlmann assays were superior with 100 % sensitivity…”.” Read Citation BÜHLMANN fCAL® ELISA is for Research Use Only.  Not for use
Continue Reading

Analytical Evaluation of a Fully Automated Immunoassay for Faecal Calprotectin in a Paediatric Setting

BÜHLMANN fCAL® turbo: Noebauer, B., Ramic, L. et al. Analytical evaluation of a fully automated immunoassay for faecal calprotectin in a paediatric setting.  Biochemia Medica, 2017;27(3):030710. DOI: 10.11613/BM.2017.030710 Highlights from this Publication “ ...With its fine performance characteristics, its strong correlation with the reference method ELISA and its convenient handling, it is a new analytical option for the rapid
Continue Reading

Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis

BÜHLMANN fCAL® ELISA: Kristensen, V., A. Roseth, et al.  Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis.  Gastroenterology Research and Practice; Volume 2017 (2017), Article ID 2098293, 5 pages.  DOI: 10.1155/2017/2098293. Highlights from this Publication “Conclusions. Fecal calprotectin <250 μg/g after medical treatment for active ulcerative colitis is a reliable marker of endoscopic
Continue Reading

Do Not Forget About Pre-Analytics in Faecal Calprotectin Measurement!

BÜHLMANN fCAL® turbo and CALEX® Cap: Oyaert, M., Van den Bremt, S. et al. Do not forget about pre-analytics in faecal calprotectin measurement! Clinica Chimica Acta. 2017 Oct; 473:124-126. doi:10.1016/j.cca.2017.08.025. PMID: 28847684 . Highlights from this Publication This study found an optimal stability of fecal calprotectin when sampled with CALEX® extraction buffer and stored at 2-8 °C for 7 days. Furthermore, the
Continue Reading

Diagnostic Accuracy of Fecal Calprotectin in Assessing the Severity of Inflammatory Bowel Disease: From Laboratory to Clinic

BÜHLMANN fCAL® ELISA: S. Moein, D. Quujeq et al. Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic. Caspian J Intern Med 2017; 8(3):178-182 DOI: 10.22088/cjim.8.3.178. Highlights from this Publication “ The current study also suggested 78.4 µg/g as the cut-off level for FC by 100% sensitivity and
Continue Reading

Turbidimetric Determination of Fecal Calprotectin Using Two Table Top Chemistry Analyzers: Mindray BS-200E and Cobas® c111

BÜHLMANN fCAL® turbo: Mandic-Havelka, A. Nilsen, T. et. al. Turbidimetric Determination of Fecal Calprotectin Using Two Table Top Chemistry Analyzers: Mindray BS-200E and Cobas® c111.  Clin Lab.  2017 May 1;63(5):907-913. doi: 10.7754/Clin.Lab.2016.161032.  PMID: 28627817 Highlights from this Publication “The assay was linear in the range between 20 and 1,900 µg/g with a limit of quantification around 20
Continue Reading